A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and a History of Statin Intolerance

Trial Profile

A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and a History of Statin Intolerance

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Hypercholesterolaemia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 18 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 07 Jun 2013 Top-line results reported in an Esperion Therapeutics media release.
    • 07 Jun 2013 Primary endpoint 'Significant decrease in LDL-cholesterol level with ETC 1002 vs placebo' has been met, according to an Esperion Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top